Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Depreciation & Amortization (CF) (2021 - 2025)

Prime Medicine (PRME) has disclosed Depreciation & Amortization (CF) for 5 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Depreciation & Amortization (CF) rose 9.26% year-over-year to $1.9 million, compared with a TTM value of $7.3 million through Dec 2025, up 19.47%, and an annual FY2025 reading of $7.3 million, up 19.47% over the prior year.
  • Depreciation & Amortization (CF) was $1.9 million for Q4 2025 at Prime Medicine, roughly flat from $1.9 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q3 2025 and bottomed at $200000.0 in Q3 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.2 million, with a median of $1.2 million recorded in 2023.
  • The sharpest move saw Depreciation & Amortization (CF) skyrocketed 259.04% in 2023, then grew 9.26% in 2025.
  • Year by year, Depreciation & Amortization (CF) stood at $200000.0 in 2021, then soared by 335.0% to $870000.0 in 2022, then skyrocketed by 43.33% to $1.2 million in 2023, then soared by 37.69% to $1.7 million in 2024, then increased by 9.26% to $1.9 million in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for PRME at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.